We are live on
!
Find out more
NC
Nexthera Capital Portfolio holdings
AUM
$120M
1-Year Est. Return
10.01%
This Fund
S&P 500
This Quarter
Est. Return
+39.41%
1 Year Est. Return
+10.01%
3 Year Est. Return
+160.68%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$82.4M
AUM Growth
-$160M
(-66%)
Cap. Flow
-$197M
Cap. Flow
% of AUM
-238.52%
Top 10 Holdings %
Top 10 Hldgs %
72.4%
Holding
35
New
12
Increased
–
Reduced
12
Closed
11
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
UroGen Pharma
URGN
|
+$5.56M |
| 2 |
Sarepta Therapeutics
SRPT
|
+$2.73M |
| 3 |
AMRN
Amarin Corp
AMRN
|
+$2.68M |
| 4 |
ACOR
Acorda Therapeutics
ACOR
|
+$2.32M |
| 5 |
Neurocrine Biosciences
NBIX
|
+$2.01M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Novartis
NVS
|
+$24.3M |
| 2 |
BOLD
Audentes Therapeutics, Inc
BOLD
|
+$14.7M |
| 3 |
Insmed
INSM
|
+$14.4M |
| 4 |
Heron Therapeutics
HRTX
|
+$11.3M |
| 5 |
Bausch Health
BHC
|
+$11M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 92.2% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
BOLD
1
DELISTED
Audentes Therapeutics, Inc
BOLD
| $9.78M | 11.87% |
250,620
-513,573
| -67% | -$14.7M |
|
|
2
Heron Therapeutics
HRTX
$87M
| $9.5M | 11.53% |
388,623
-430,541
| -53% | -$11.3M |
|
|
3
Insmed
INSM
$23.4B
| $8.26M | 10.03% |
284,263
-554,683
| -66% | -$14.4M |
|
|
IMMU
4
DELISTED
Immunomedics Inc
IMMU
| $6.43M | 7.8% |
334,724
-559,955
| -63% | -$9.03M |
|
|
5
Bausch Health
BHC
$1.66B
| $5.08M | 6.16% |
205,660
-459,177
| -69% | -$11M |
|
|
6
UroGen Pharma
URGN
$2.06B
| $4.9M | 5.94% |
+132,589
| New | +$5.56M |
|
|
GBT
7
DELISTED
Global Blood Therapeutics, Inc.
GBT
| $4.61M | 5.59% |
87,099
-134,563
| -61% | -$6.61M |
|
|
STML
8
DELISTED
Stemline Therapeutics, Inc.
STML
| $4.18M | 5.08% |
325,526
-386,032
| -54% | -$4.36M |
|
|
9
Novartis
NVS
$296B
| $3.83M | 4.65% |
50,587
-302,200
| -86% | -$24.3M |
|
|
AMRN
10
Amarin Corp
AMRN
$284M
| $3.09M | 3.75% |
+7,435
| New | +$2.68M |
|
|
CBAY
11
DELISTED
Cymabay Therapeutics
CBAY
| $2.79M | 3.39% |
210,257
-504,507
| -71% | -$5.37M |
|
|
12
Sarepta Therapeutics
SRPT
$1.67B
| $2.54M | 3.08% |
+21,270
| New | +$2.73M |
|
13
uniQure
QURE
$2.65B
| $2.31M | 2.81% |
+38,800
| New | +$1.73M |
|
14
Exelixis
EXEL
$14B
| $2.15M | 2.61% |
90,356
-217,383
| -71% | -$4.96M |
|
|
15
Neurocrine Biosciences
NBIX
$17.5B
| $2.12M | 2.57% |
+24,040
| New | +$2.01M |
|
|
ACOR
16
DELISTED
Acorda Therapeutics
ACOR
| $2.06M | 2.5% |
+1,290
| New | +$2.32M |
|
|
AGN
17
DELISTED
Allergan plc
AGN
| $2.01M | 2.43% |
+13,700
| New | +$1.99M |
|
|
ICPT
18
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
| $1.34M | 1.62% |
+11,952
| New | +$1.31M |
|
19
Kiniksa Pharmaceuticals
KNSA
$4.82B
| $1.22M | 1.48% |
+67,692
| New | +$1.31M |
|
|
CHMA
20
DELISTED
Chiasma, Inc. Common Stock
CHMA
| $1.06M | 1.29% |
203,948
-862,491
| -81% | -$3.8M |
|
|
DCPH
21
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
| $995K | 1.21% |
42,865
-79,027
| -65% | -$2.07M |
|
|
SAGE
22
DELISTED
Sage Therapeutics
SAGE
| $986K | 1.2% |
+6,200
| New | +$898K |
|
23
BioMarin Pharmaceuticals
BMRN
$11.4B
| $733K | 0.89% |
+8,250
| New | +$765K |
|
24
Madrigal Pharmaceuticals
MDGL
$12.5B
| $432K | 0.52% |
+3,452
| New | +$429K |
|
|
25
CALL
BioMarin Pharmaceuticals
BMRN
$11.4B
| – | – |
-341,400
| Closed | -$29.1M |
|
Similar funds
KAM
VCP
PFC
FCA
TA
EBIM
BCM
ACP
Nexthera Capital's Q1 2019 Portfolio in Review
As of Q1 2019, Nexthera Capital held 35 positions worth $82.4M, down 66% from $243M the previous quarter. Its ten largest holdings account for 72% of the portfolio.
Nexthera Capital withdrew a net $197M in Q1 2019, closing 11 positions and reducing 12 holdings. Its most notable exit was Horizon Therapeutics Public Limited Company Ordinary Shares, an estimated $7.74M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 92% of assets, up from 57% a quarter earlier.
Against the trend, Nexthera Capital opened a new position in UroGen Pharma worth $4.9M.
- Nexthera Capital's largest Q1 2019 buy was UroGen Pharma: 132,589 shares worth $4.9M.
- Nexthera Capital's biggest Q1 2019 reduction was Novartis, cutting an estimated $24.3M.
- Nexthera Capital fully exited Horizon Therapeutics Public Limited Company Ordinary Shares in Q1 2019, selling an estimated $7.74M.
- Nexthera Capital's ten largest holdings make up 72% of its $82.4M portfolio in Q1 2019.
- Nexthera Capital opened 12 new positions and closed 11 in Q1 2019.
- Nexthera Capital's portfolio value fell 66% quarter-over-quarter to $82.4M.
Based on Nexthera Capital's 13F filing for Q1 2019, filed 15 May 2019.